Name: Gyre Therapeutics, Inc. (CBIO) Cash Flow Statement
Creator: FinSpry

Gyre Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Gyre Therapeutics, Inc. (CBIO) - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Operating Activities
Net Income	-71.47	-36.90	-46.69	-63.43	-51.03	-57.89	-48.27
Depreciation & Amortization	0.04	1.01	1.03	1.01	0.95	0.90	0.28
Stock Based Compensation	4.54	0.00	0.00	0.00	0.00	0.00	0.00
Change in Working Capital	37.85	-1.02	-5.17	-0.27	4.74	-0.58	0.08
Change in Accounts Payable	29.31	0.00	0.00	0.00	0.00	0.00	0.00
Change in Other Working Capital	8.54	0.00	0.00	0.00	0.00	0.00	0.00
Other Operating Activities	0.01	2.02	4.37	5.19	6.10	5.59	0.00
Net Cash from Operating Activities	-25.08	-34.88	-46.46	-57.49	-39.24	-51.98	-43.33
Investing Activities
Capital Expenditures	-0.01	0.02	0.08	0.01	0.07	0.14	-0.13
Acquisitions	0.03	0.00	0.00	0.00	0.00	0.00	0.00
Net Cash from Investing Activities	0.02	-0.02	-0.08	-0.01	-0.07	-0.14	-0.13
Financing Activities
Common Stock Issued	1.26	28.71	4.16	10.70	17.82	0.00	128.43
Other Financing Activities	-3.04	0.00	0.00	0.00	0.00	0.00	0.00
Net Cash from Financing Activities	164.14	28.82	4.16	10.72	18.14	0.41	129.45
Summary
Net Change in Cash	139.06	-6.08	-42.38	-46.78	-21.17	-51.72	85.99
Cash at Beginning of Period	41.79	0.00	90.25	137.04	158.20	209.92	123.92
Cash at End of Period	10.72	-6.08	47.87	137.04	137.04	158.20	209.92
Free Cash Flow	-31.11	-34.90	-46.54	-57.50	-39.31	-52.13	-43.46